Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Depression 2Spinal Cord Neoplasms 1Sleep Initiation and Maintenance Disorders 1Pain, Postoperative 1Pain 1Ovarian Neoplasms 1Breast Neoplasms 1Breast Cancer Surgery 1Anxiety Disorders 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × Esketamine × Clear all
NCT06624878 2026-02-27

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Zhejiang Cancer Hospital

Phase NA Completed
568 enrolled
Gynecologic

Depression, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡